<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120327</url>
  </required_header>
  <id_info>
    <org_study_id>Amlodipine study</org_study_id>
    <nct_id>NCT01120327</nct_id>
  </id_info>
  <brief_title>A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients</brief_title>
  <official_title>A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. OBJECTIVES

           Primary objective to evaluate the difference of the peak oxygen uptake change (VO2 max,
           mL/kg/min) in amlodipine group against no CCB group at 9 months

           Secondary objectives To evaluate the change of sublingual nitrate use per day against no
           CCB group at 1 and 3 months To evaluate the change of biomarkers against no CCB group at
           9 months

        2. SUBJECTS AND CENTERS 212, stable angina patients with angiographically confirmed
           significant residual stenosis 10, 3rd-grade, teaching hospitals in Korea
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>9 months</time_frame>
    <description>Difference of the peak oxygen uptake change (VO2 max, mL/kg/min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sublingual Nitrate</measure>
    <time_frame>1month and 3 months</time_frame>
    <description>To evaluate the change of sublingual nitrate use per day against no CCB group at 1 and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate the change of biomarkers against no CCB group at 9 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable angina patient with angiographically confirmed significant residual stenosis

          -  Stenosis more than 50% in 2 major coronary arteries at least or Stenosis more than 75%
             in 1 major coronary artery

        Exclusion Criteria:

          -  No other pulmonary/psychiatry/musculoskeletal disorder limiting CPET

          -  Contraindicated to the CPET (e.g. unstable angina, aortic stenosis, uncontrolled
             hypertension, uncontrolled asthma, hypoxemia at rest, epilepsy, locomotor disorder,
             severe hypertension and febrile illness)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hae-Young Lee, MD, PhD</last_name>
    <phone>82-10-4528-6160</phone>
    <email>hylee612@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hae-Young Lee, MD, PhD</last_name>
      <phone>82-10-4528-6160</phone>
      <email>hylee612@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>May 7, 2010</last_update_submitted>
  <last_update_submitted_qc>May 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo, Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

